Go Back
Report Abuse

Sickle Cell Disease Association of America

Description

The Sickle Cell Disease Association of America (SCDAA) is the only US national patient advocacy organisation for the estimated 100,000 Americans living with sickle cell disease and the 3 million with sickle cell trait — a rare inherited haemoglobinopathy disproportionately affecting African-American, Hispanic, and South Asian populations. Founded in 1971, SCDAA operates a national network of 50+ community-based organisations and has played a central role in securing FDA approval of hydroxyurea, L-glutamine (Endari), crizanlizumab (Adakveo), voxelotor (Oxbryta), and the gene therapies exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) in 2023. The Association advocates for sickle cell newborn screening, pain management protocols, and health equity.

Contact

Address
3700 Koppers Street, Suite 570, Baltimore, MD 21227, USA
Zip/Post Code
21227
3700 Koppers Street, Suite 570, Baltimore, MD 21227, USA
Social Info

Rare Disease Watch

Our aim is to make complex information clear, accessible, and trustworthy. With concise reporting and consistent daily coverage, Rare Disease Watch helps professionals, patients, advocates, and families stay informed about what is changing in the rare disease landscape and why it matters.
All Rights Reserved. Rare Disease Watch©. Part of Honnao Ltd, Registered in England and Wales, Company number: 12345498. Trading Address: Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram